Today: 30 June 2026
Browse Category

EPA:ABVX.PA 10 December 2025 - 12 January 2026

Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax Société Anonyme is back in the spotlight on December 10, 2025, after its share price spiked again on fresh takeover speculation involving U.S. pharma giant Eli Lilly. The move caps an extraordinary year in which the French biotech has transformed from a relatively obscure name into a multibillion‑euro inflammatory bowel disease contender.Reuters+1 Below is a detailed rundown of today’s news, the fundamental drivers, and the latest forecasts and analyses being published about Abivax.
10 December 2025
····

Stock Market Today

  • Concentrix Q2 EPS Comes In Light, Stock Down Nearly 40% for the Year
    June 29, 2026, 7:00 PM EDT. Concentrix (CNXC) posted Q2 earnings of $2.63 a share, a penny below the Zacks Consensus of $2.64. Revenue was $2.46 billion, a 0.43% miss versus estimates, but up from $2.42 billion last year. Concentrix has only topped earnings estimates once in the past four quarters. Shares have dropped about 39.9% since the start of the year, trailing the S&P 500, which is up 7.4%. CNXC has a Zacks Rank #3 (Hold) as earnings estimate revisions remain uneven. Analysts are looking for $3.18 EPS and $2.54 billion revenue next quarter; full-year revenue is forecast at $11.65 billion. The Business-Services group sits in the top 42% of Zacks sectors. Investors are focused on the company's earnings call for any update on guidance.
Go toTop